Blair William & Co. IL decreased its holdings in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 38.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 754,745 shares of the biopharmaceutical company’s stock after selling 480,972 shares during the quarter. Blair William & Co. IL’s holdings in Bristol-Myers Squibb were worth $42,054,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of the stock. State Street Corp lifted its stake in Bristol-Myers Squibb by 1.8% during the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after purchasing an additional 1,223,457 shares during the last quarter. Jennison Associates LLC lifted its stake in Bristol-Myers Squibb by 0.8% during the first quarter. Jennison Associates LLC now owns 21,927,898 shares of the biopharmaceutical company’s stock worth $1,192,439,000 after purchasing an additional 178,436 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Bristol-Myers Squibb by 18.7% during the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after purchasing an additional 2,451,390 shares during the last quarter. Legal & General Group Plc lifted its stake in Bristol-Myers Squibb by 2.7% during the second quarter. Legal & General Group Plc now owns 8,431,348 shares of the biopharmaceutical company’s stock worth $469,802,000 after purchasing an additional 217,920 shares during the last quarter. Finally, Swiss National Bank lifted its stake in Bristol-Myers Squibb by 27.2% during the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after purchasing an additional 1,267,900 shares during the last quarter. Hedge funds and other institutional investors own 68.93% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE BMY) opened at 61.66 on Wednesday. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $66.10. The stock’s 50 day moving average price is $63.47 and its 200 day moving average price is $57.76. The stock has a market cap of $101.12 billion, a PE ratio of 22.52 and a beta of 1.19.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period last year, the business posted $0.77 EPS. On average, equities research analysts anticipate that Bristol-Myers Squibb Company will post $2.99 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 2.53%. The ex-dividend date is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 61.42%.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total value of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.23% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Bristol-Myers Squibb Company (BMY) Position Trimmed by Blair William & Co. IL” was reported by Community Financial News and is the property of of Community Financial News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/11/01/bristol-myers-squibb-company-bmy-position-trimmed-by-blair-william-co-il.html.
BMY has been the subject of several recent analyst reports. Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 price objective for the company. in a research note on Wednesday, August 9th. Jefferies Group LLC reiterated a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Wednesday, July 12th. Finally, UBS AG reiterated a “buy” rating and issued a $72.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. One analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $64.73.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
What are top analysts saying about Bristol-Myers Squibb Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb Company and related companies.